4Soper CP, Latif AB, Bending MR. Amelioration of hepatorenal syndrome with selective endothelin-A antagonist. Lancet, 1996,347: 1842-1843.
5Duvoux C, Zanditenas D, Hezode C, et al. Noradrenaline for treatment of type lhepatorenal syndrome (HRS). J Hepatol, 2001, 34(Suppl.1): 18.
6Holt S, Goodier D, Marley R, et al. Improvement in renal function in hepatorenal syndrome with N-acetylcysteine. Lancet, 1999, 353:294-295.
7Daskalopoulos G. Randomized trial of peritoneovenous shunt (PVS)in the treatment of hepatorcnal syndrome (HRS). Gastroenterology,1995, 88: 88.
8Runyon BA. Management of adult patients with ascites caused by cirrhosis. Hepatology, 1998, 27: 264-272.
9Bilbao JI, Quiroga J, Herrero JI, et al. Transjugular intrahepatic portosystemic shunt (TIPS): current status and future possibilities.Cardiovasc Intervent Radiol, 2002, 25:251-269.
10Mitzner SR, Stange J, Klarmnt S, et al. Extracorporeal detoxification using the molecular adsorbent recirculating system for critically ill patients with liver failure. J Am Soc Nephrol, 2001, 12 (Suppl17): S75-82.
